医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

joimax® Obtains Full Product Registration in Thailand, and is Now Active in 10 Asian Countries

2017年02月28日 AM04:54
このエントリーをはてなブックマークに追加


 

IRVINE, Calif.

joimax® further ensures its market access in Asia. The German based market leader of technologies and training methods for endoscopic minimally invasive spinal surgery is expanding its presence and recently has obtained full product registration from the Thai Food & Drug Administration (FDA). joimax® also has approvals in South Korea, China, Singapore, Indonesia, Hong Kong and Vietnam. For Malaysia, Taiwan and Japan, the certification for the product range is expected in 2017. “We are constantly pushing the registration process in Asia to extend the availability of joimax® products. Thus, joimax® is well prepared to further widen its market presence in Asia, demonstrating our commitment to the fastest growing region of the world,” states Wolfgang Ries, Founder and CEO of joimax®.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170227006409/en/

Participants of the National Minimal Invasive Spinal Summit Forum & 4th joimax User Meeting, held in ...

Participants of the National Minimal Invasive Spinal Summit Forum & 4th joimax User Meeting, held in Zhenghou City, China from Dec. 23rd until 25th, 2016 (Photo: Business Wire)

For years, joimax® has been working with the Korean Wooridul group, the world’s largest Specialized Spine Hospital Network. Starting in 2017, joimax®, together with the Wooridul Hospital in Seoul, will offer International courses for Minimally Invasive Spinal Surgery (MISS). In a series of four courses, provided in basic and advanced level, the education of international spine surgeons is ensured. The first one, chaired by joimax® faculty Dr. Sang-Ho Lee, South Korea, recently took place. The one-week training programs offer surgeons the opportunity to learn percutaneous endoscopic techniques and other minimally-invasive procedures with lectures, operation observation and hands-on-workshops. Since 2004, more than 600 spine surgeons and specialists from 41 countries have participated in these courses at Wooridul.

After the National Minimal Invasive Spinal Summit Forum, together with the 4th joimax® User Meeting in December, joimax® China, headquartered in Chengdu, will celebrate its 10th birthday in April 2017. On this occasion, numerous internationally well-known faculties will meet in Chongqing, China to share experience and expertise. Lectures and live surgeries are planned to be held in two hospitals and to be broadcasted via Internet.

About joimax®

Founded in Karlsruhe, Germany, in 2001, joimax® is the leading developer and marketer of complete systems for endoscopic minimally invasive spinal surgery. With TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) for decompression procedures, MultiZYTE® RT (e.g. for rhizotomy) and with MultiZYTE® SI for SI-Joint therapy or with EndoLIF® and Percusys® for endoscopic minimally-invasive assisted stabilizations, proven endoscopic systems are provided that, together, cover a whole variety of indications.

In procedures for herniated disc, stenosis, pain therapy or spinal stabilization treatment, surgeons utilize joimax® technologies to operate through small incisions – under local or full anesthetic – via tissue and muscle-sparing corridors through natural openings into the spinal canal (e.g. intervertebral foramen, the “Kambin triangle”).

View source version on businesswire.com: http://www.businesswire.com/news/home/20170227006409/en/

CONTACT

Press Contact USA:
joimax® Inc.
Melissa Brumley,
001 949 859 3472
Melissa.brumley@joimaxusa.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease